This study is looking for adults aged 18 and older who have type 2 diabetes and are overweight or obese (BMI of 27.0 kg/m2 or higher). You also need to have a specific blood sugar level (HbA1c between 7% and 10%). The goal is to see if adding AT673 to semaglutide helps with weight loss and blood sugar control more than semaglutide alone. Researchers will compare two different doses of AT673 against a placebo (an inactive substance) when given with semaglutide. The main thing they will measure is body weight after 13 weeks. The study also looks at how AT673 affects your blood sugar (HbA1c) and how safe it is. The current status of this study is unclear, and it plans to enroll about 150 participants.

Study design

This is a phase 2, double-blind, placebo-controlled study, meaning neither you nor your doctor will know if you are receiving AT673 or a placebo. About 150 participants will be randomly assigned to one of three groups.

What's involved

You will start semaglutide and gradually increase the dose. At the same time, you will receive weekly injections of AT673 or a placebo for 13 weeks, followed by a 4-week safety check. Your total participation will be about 17 weeks.

Compensation

Not stated in the trial record.

Follow-up

After your 13 weeks of treatment, there will be a 4-week safety follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.